Skip to content
DataLookout
Menu

NCT05431595

Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy

StatusActive, Not Recruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 9 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 21 words
    • Enrollment closed, study ongoing
    • Enrollment target: estimated 42 to confirmed 41
    • Site details revised
  2. Minor Enrollment target: 30 to 42v11
  3. Minor Site contact updatedv10
  4. Notable Trial status: Active, Not Recruiting to Recruiting
    • Enrollment target: 11 to 30
    • Site details revised
    v9
  5. Notable Enrollment target: estimated 150 to confirmed 11
    • Trial status: Enrolling by Invitation to Active, Not Recruiting
    v7
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Eligibility criteria expanded, about 4 wordsv4
  2. Notable Primary and study completion dates: Aug 1, 2025 to Feb 2, 2027
    • Trial status: Recruiting to Enrolling by Invitation
    • Start date changed from estimate of Dec 30, 2022 to Jul 19, 2022
    • Site details revised
    v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Edmonton Symptom Assessment Scale Questionnaire
Timeframe: through study completion, an average of 1 year

Arms and interventions

Group 1Experimental

Participants will receive haloperidol by vein every 12 hours (or more often, as needed).

Group 2Experimental

Participants will receive chlorpromazine by vein every 12 hours (or more often, as needed).

Group 3Experimental

Participants will receive valproate by vein every 12 hours.

Group 4Experimental

Participants will receive placebo every by vein every 12 hours.

Drugs: Haloperidol, Chlorpromazine, Valproate, Placebo

Sites

1 site in 1 country

  • MD Anderson Cancer CenterHouston, Texas, United States